Current state of type 2 diabetes management

American Journal of Managed Care

Volumn 19, Issue 8 SUPPL, 2013, Pages

  Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; INSULIN DERIVATIVE; LIRAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; A1CF PROTEIN, HUMAN; INSULIN; RNA BINDING PROTEIN;

ACUTE PANCREATITIS; ANTIDIABETIC ACTIVITY; ARTICLE; CARBOHYDRATE ABSORPTION; COMORBIDITY; FOOD AND DRUG ADMINISTRATION; GLUCONEOGENESIS; GLUCOSE ABSORPTION; GLUCOSE HOMEOSTASIS; GLUCOSURIA; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTESTINE ABSORPTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; BLOOD; DRUG ANTAGONISM; DRUG COMBINATION; HEALTH CARE SURVEY; PHYSIOLOGY; UNITED STATES;

DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; PRACTICE GUIDELINES AS TOPIC; RNA-BINDING PROTEINS; SODIUM-GLUCOSE TRANSPORTER 2; UNITED STATES;

EID: 84899057527     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553. (Pubitemid 28319935)
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(suppl 1):S62-S69.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
4. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care. 2013;36(suppl 1):S11-S66.
5. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443-453.
6. Ali MK, McKeever Bullard K, Imperatore G, Barker L, Gregg EW; Centers for Disease Control and Prevention (CDC). Characteristics associated with poor glycemic control among adults with self-reported diagnosed diabetes - National Health and Nutrition Examination Survey, United States, 2007-2010. MMWR Morb Mortal Wkly Rep. 2012;61(suppl):32-37.
7. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385-411. (Pubitemid 40227460)
8. Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: an update. Clinical Diabetes. 2005;23(2):64-76. (Pubitemid 40965047)
9. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. (Pubitemid 44912190)
10. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638-2643. (Pubitemid 44912191)
11. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303. (Pubitemid 29383658)
12. Actos [package insert]. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc; 2011.
13. Buse JB, Polonsky KS, Burant CF. Type 2 diabetes mellitus. In: Larsen PR et al, eds. Williams Textbook of Endocrinology. 10th ed. Philadelphia, PA: WB Saunders; 2003:1427-1483.
14. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2008.
15. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patient with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612-4619. (Pubitemid 44833446)
16. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care. 2010;33(11): 2349-2354.
17. Eckerle Mize DL, Salehi M. The place of GLP-1-based therapy in diabetes management: differences between DPP-4 inhibitors and GLP-1 receptor agonists. Curr Diab Rep. 2013;13(3):307-318.
18. Verspohl EJ. Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacol Rev. 2012;64(2):188-237.
19. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004;447:510-518. (Pubitemid 38241437)
20. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol. 1996;270(4, pt 1):G541-G553.
21. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875-883.
22. Silverman M, Turner RJ. Glucose transport in the renal proximal tubule. In: Windhager EE, ed. Handbook of Physiology: Renal Physiology. New York, NY: Oxford University Press; 1992:2017-2038.
23. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.
24. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6 suppl):S37-S50.
25. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
26. Handelsman Y, Mechanick JI, Blonde L, et al; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17(2):287-302.
27. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2012;156(3):218-231.
28. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352(2):174-183. (Pubitemid 40096614)
29. Rachmiel M, Perlman K, Daneman D. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am. 2005;52(6):1651-1675. (Pubitemid 41654733)